Tango Therapeutics, Inc. TNGX R2KR3KPHARMA
Company Overview
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Why Investors Should Care
Revenue has grown at a 35.9% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $62.38M (+48.3% YoY); net profit $-101.59M.
- Trailing 12 Months Year-on-year growth — revenue +48.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 35.9%, profit CAGR 2.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 35.89% |
| 1 Year: | 48.29% |
Compounded Profit Growth
| 5 Years: | 2.03% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +239.24% |
| 6 Months: | -9.43% |
| 3 Months: | -12.65% |
| 1 Month: | -5.24% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)47.72 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 35.9% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 29.1% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TNGX Tango Therapeutics, Inc. R2KR3KPHARMA | 23.34 | -27.79 | $3.94B | 0.00% | -29.52% | -21.34% | 35.89% | 2.03% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | -11.26M | 6.39M | 18.15M | 6.79M | 5.76M | 5.77M | 6.92M | 5.77M | 14.60M | 10.73M | 6.47M | 19.88M | 11.61M | 5.39M | 3.18M | 53.81M | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 47.92M | 44.15M | 39.74M | 41.86M | 48.77M |
| Operating Income | - | - | -26.76M | -12.08M | -4.56M | -19.57M | -25.38M | -25.20M | -29.92M | -30.29M | -23.25M | -25.63M | -42.26M | -29.55M | -32.88M | -42.53M | -40.97M | 14.07M | -41.86M | -48.77M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -41.91M | -40.34M | 14.63M | -41.38M | -48.31M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -39.84M | -38.82M | 15.87M | -38.80M | -45.51M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.00K | 35.00K | -10.00K | -55.00K | 1.00K |
| Net Income | -7.91M | -8.39M | -26.80M | -12.11M | -4.49M | -19.59M | -25.21M | -24.86M | -29.05M | -28.01M | -20.71M | -22.26M | -37.91M | -25.55M | -29.17M | -39.88M | -38.85M | 15.88M | -38.75M | -45.51M |
| Diluted EPS | - | - | - | - | -0.09 | -0.28 | -0.29 | -0.28 | -0.33 | -0.32 | -0.23 | -0.23 | -0.35 | -0.24 | -0.27 | -0.36 | -0.35 | 0.13 | -0.29 | -0.32 |
| R&D Expense | - | - | 12.98M | 15.00M | 19.08M | 21.92M | 24.33M | 23.74M | 28.74M | 28.04M | 28.67M | 27.15M | 38.06M | 38.65M | 33.26M | 36.44M | 32.81M | 30.82M | - | 33.53M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 7.66M | 37.04M | 24.86M | 36.53M | 42.07M | 62.38M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 135.93M | 150.70M | 187.66M | 173.67M |
| Operating Income | -52.20M | -58.19M | -111.07M | -114.17M | -145.59M | -111.29M |
| EBITDA | - | - | -109.46M | -111.76M | -143.10M | -109.01M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | - | -108.12M | -101.61M | -130.09M | -101.59M |
| Tax Provision | - | - | 54.00K | 134.00K | 208.00K | 4.00K |
| Net Income | -51.97M | -58.23M | -108.18M | -101.74M | -130.30M | -101.59M |
| Diluted EPS | - | -0.94 | -1.23 | -1.08 | -1.19 | -0.87 |
| R&D Expense | 49.99M | 77.64M | 105.91M | 115.20M | 143.92M | 132.16M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 207.25M | 500.15M | 436.47M | 402.57M | 316.49M | 398.69M |
| Total Equity | 7.91M | 38.60M | 344.75M | 249.48M | 253.11M | 199.52M | 346.18M |
| Cash & Equivalents | - | 28.38M | 142.75M | 59.97M | 66.39M | 69.53M | 112.28M |
| Total Liabilities | - | 168.65M | 155.41M | 186.99M | 149.46M | 116.97M | 52.51M |
| Current Liabilities | - | 40.92M | 40.69M | 55.55M | 45.94M | 38.17M | 21.68M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 70.07M | -59.53M | -109.08M | -117.98M | -131.50M | -138.89M |
| Investing Cash Flow | -145.47M | -183.43M | 26.40M | 41.43M | 86.13M | -40.87M |
| Financing Cash Flow | 80.88M | 357.32M | 1.61M | 82.41M | 47.66M | 222.50M |
| Capital Expenditure | -1.11M | -1.84M | -7.69M | -1.53M | -754.00K | -1.05M |
| Free Cash Flow | 68.97M | -61.36M | -116.77M | -119.51M | -132.25M | -139.93M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | -681.8% | -157.1% | -446.8% | -312.6% | -346.1% | -178.4% |
| Net Margin % | -678.8% | -157.2% | -435.1% | -278.5% | -309.7% | -162.9% |
| ROE % | -134.6% | -16.9% | -43.4% | -40.2% | -65.3% | -29.3% |
| ROCE % | -31.4% | -12.7% | -29.2% | -32.0% | -52.3% | -29.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RTW Investments LP | 8.24% | 13.90M | $330.97M |
| 2 | Blackrock Inc. | 7.38% | 12.44M | $296.16M |
| 3 | FMR, LLC | 7.31% | 12.33M | $293.66M |
| 4 | Farallon Capital Management LLC | 7.28% | 12.28M | $292.32M |
| 5 | Boxer Capital Management, LLC | 6.45% | 10.88M | $258.96M |
| 6 | Goldman Sachs Group Inc | 5.92% | 9.98M | $237.64M |
| 7 | TCG Crossover Management, LLC | 5.39% | 9.08M | $216.22M |
| 8 | TRV GP IV, LLC | 3.78% | 6.37M | $151.78M |
| 9 | Paradigm Biocapital Advisors LP | 3.77% | 6.36M | $151.37M |
| 10 | Price (T.Rowe) Associates Inc | 3.77% | 6.35M | $151.17M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TNGX
Tango Therapeutics (TNGX) Stock Looks Fully Valued After A 252% Run - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQajJNVHh3RTlIa0RiQkNVOTItWm9CMFJ3NFI1WVVjUlREY1djRnBHMnFiQ005dEFPUVFTRDlDdmN4bXZTVXk0eEpndDAxWnZwXzgxcEpTOHZqeUxJM0ktRzhycE5Cck1rTW5FT1h5UHY1SWk5TlI0Tm9BWGxhdjdNQU1abXlMQ1k4ejRjeD…
Tango Therapeutics stock falls despite positive cancer trial data - Investing.com
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNRXV2RlRKSlhaOTNjV3FBYklmNmcwYWdFSFNGNGxlTFR2MEw4LS01Vjh3VDc2SFdYWmNicVJfR2hjdWY4N2ZfT1ZOZlg5LWkxZERqbWJzVVRvRW9qeGc5NGQ5NVpaSm5SR1MxdFdYaDFJcjA4QTNBaVQ1VHdrZVB2TDVHbndJQXNQWnBTVV…
Tango Therapeutics, Inc. Estimates – NASDAQ:TNGX - TradingView
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE1TNEFpV2ZsQ0RlMTY0ZndINkJaXzkwRnhiMUZSN09GX1FNT1hxbkprLWN5V2FYVEttWXpLTEJoMFdhOHZ4djRGa29OYlp3dkhqenRYU283QzRMYlpfX0VqTngyVURDWGQyX0FBVGdQNWRDQ2N1YlJ6WA?oc=5" target="_blank">Tango…
Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data? - Benzinga
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxQYWlDVFZOengzV3gxc2xmYWJsTXJMazhzVk9HRXRjbnU5bTlTVXg4Q2tEdERxSXZBQUloeTVvVnpISTBYOXVSNjVEN0dOcTV1YjdNNG5vd1djbExya2wtYlM4VmlQVldTbmpGSUhBNUhSVGJUVFEtd0hqMTNnS3NjQmZUUXFJQXEzUU4wb2…
At nine months, 88% of 22 pancreatic cancer patients were alive without their cancer worsening. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxPRkM1UUMwbmVZS1V4VTk1SXNaY0M1N3I5X2VTNVV2d01uTlU2RjdCZG90S1BNc1FlX0hMWHpCd2hERjRCNXd3MlJycTdaNmpsaXZTZHI0SFotSDRJOVBNdmlzNWhoR0dERHRHSks0NlkwLXdibl9XM0l4SVlyYzljNXhna0VVYVpPNXZRUD…
TNGX Feb 2027 29.000 put (TNGX270219P00029000) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE5qV1ZmUnluUXdVdDBGdFNKZGlEQURQQm9yYUdoTXAzSzdZMnFYbjl6QmZDNkVVLWVFMWUxcE45UGppQ083RVpabGpWcDVaczA4c0VjcFFaUDJzQkZEVmR3WnBvYVphZw?oc=5" target="_blank">TNGX Feb 2027 29.000 put (TNG…
TNGX — Frequently Asked Questions
What is the current share price of Tango Therapeutics, Inc. (TNGX)?
As of 2026-10-23 16:27 PDT, Tango Therapeutics, Inc. (TNGX) trades at $23.34 on NasdaqGM. Its 52-week range is $6.36 to $32.90.
What is the market capitalisation of TNGX?
Tango Therapeutics, Inc. (TNGX) has a market capitalisation of $3.94B on NasdaqGM.
What is the P/E ratio of TNGX?
TNGX trades at a trailing price-to-earnings (P/E) ratio of -27.79. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 8.01.
What is the return on equity (ROE) of TNGX?
TNGX has a return on equity (ROE) of -21.34%. Its return on capital employed (ROCE) is -29.52%.
Is TNGX a good stock to buy?
This page provides a data-driven analysis of Tango Therapeutics, Inc. (TNGX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.